Two ways to keep up, starting from a different place. Take one, or both.
For following the competition: what moved in each program, several studies read as one move.
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Cirrhosis, Familial, with Pulmonary Hypertension to watchlistEvery Monday by email · turn it off any timePro · free during the beta
For keeping up with the studies themselves: each open study, one by one, and any new one that matches.
Saturdays · came in, left, changed
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Free · up to 2,000 studies across your alerts
The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 37 studies for Cirrhosis, Familial, with Pulmonary Hypertension across 8 countries. 26 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-11-10.
Tianjin Medical University Cancer Institute and Hospital (3) · First Affiliated Hospital, Sun Yat-Sen University (2) · Sun Yat-sen University (2) · Shanghai Zhongshan Hospital (2) · Shengjing Hospital (2) · City of Hope Medical Center (2) · Erasmus Medical Center (2) · Harbin Medical University (1)
Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 0 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
| Drug | Leading trial sponsor · rights | Companies, last 5 years |
|---|---|---|
OxaliplatinRecent, limitedPhase 4 trial recordedEvidence
| Sanofi35% of its industry studies | 11 study |
FluorouracilRecent, limitedEvidence
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 11 study |
LeucovorinRecent, limitedEvidence
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 11 study |
2 more in limited or earlier use — sign in to see them, free.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
Drugs under test in Cirrhosis, Familial, with Pulmonary Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Lenvatinib | 5 | 1 | 6 |
| Gemcitabine | 2 | 0 | 2 |
| Cisplatin | 2 | 0 | 2 |
| Adebrelimab | 2 | 0 | 2 |
| Fluorouracil | 1 | 0 | 2 |
| Daraxonrasib | 1 | 0 | 1 |
| Celecoxib | 1 | 0 | 1 |
| Donafenib | 1 | 0 | 1 |
| Pucotenlimab | 1 | 0 | 1 |
| Folfox protocol | 1 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 8 open · Immune checkpoint inhibitors 6 open · Antimetabolites 3 open
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 16 Cirrhosis, Familial, with Pulmonary Hypertension studies recruiting now, 7 (44%) set no upper age limit and 5 (31%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 16 (100%) | 16 (100%) |
| 30 | 16 (100%) | 16 (100%) |
| 40 | 16 (100%) | 16 (100%) |
| 50 | 16 (100%) | 16 (100%) |
| 65 | 16 (100%) | 16 (100%) |
| 75 | 15 (94%) | 15 (94%) |
| 85 | 9 (56%) | 9 (56%) |
Across all 37 studies, recruiting or not: 22% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Recruiting first, then most recently updated. Showing 37 of 37. search them.